keyword
MENU ▼
Read by QxMD icon Read
search

bnp, heart failure

keyword
https://www.readbyqxmd.com/read/28088188/incidence-and-predictors-of-left-ventricular-remodeling-among-elderly-asian-women-a-community-based-cohort-study
#1
Jing Wu, Caiqin Wu, Wenjing Fan, Jie Zhou, Ling Xu
BACKGROUND: Left ventricular (LV) remodeling is closely linked to the progression of heart failure. There are limited data on the epidemiology of new onset LV remodeling among elderly women, which requires further investigation. METHOD: We examined data from a community-based cohort of women aged > 65 years, who had received > 2 echocardiography scans from 2009 to 2014. Exclusion criteria for patients included prior echocardiographic evidence of left ventricular enlargement (LVE) or hypertrophy (LVH)...
January 14, 2017: BMC Geriatrics
https://www.readbyqxmd.com/read/28087179/value-of-serum-n-terminal-b-type-natriuretic-peptide-in-asymptomatic-structural-heart-disease-in-taiwanese-population-comparisons-with-current-esc-guidelines
#2
Ta-Chuan Hung, Kuang-Te Wang, Chun-Ho Yun, Jen-Yuan Kuo, Charles Jia-Yin Hou, Chia-Yuan Liu, Tung-Hsin Wu, Hiram G Bezerra, Hsiao-Yang Cheng, Chung-Lieh Hung, Hung-I Yeh
BACKGROUND: The relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac structural or functional anomalies in pre-clinical, asymptomatic Asian populations has not been well identified. METHODS: From October 2005 to March 2008, we enrolled consecutive asymptomatic adults with preserved global left ventricular (LV) function (ejection fraction>50%) who underwent annual cardiovascular health survey. Circulating NT-proBNP was used to identify echo-defined cardiac structural/functional anomalies and compared to current recommended cut-off from the European Society of Heart Failure...
December 29, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28069685/associations-of-body-mass-index-with-laboratory-and-biomarkers-in-patients-with-acute-heart-failure
#3
Koen W Streng, Jozine M Ter Maaten, John G Cleland, Christopher M O'Connor, Beth A Davison, Marco Metra, Michael M Givertz, John R Teerlink, Piotr Ponikowski, Daniel M Bloomfield, Howard C Dittrich, Hans L Hillege, Dirk J van Veldhuisen, Adriaan A Voors, Peter van der Meer
BACKGROUND: Plasma concentrations of natriuretic peptides decline with obesity in patients with heart failure. Whether this is true for other biomarkers is unknown. We investigated a wide range of biomarker profiles in acute heart failure across the body mass index (BMI) spectrum. METHODS AND RESULTS: A total of 48 biomarkers, assessing multiple pathophysiological pathways, were measured in 2033 patients included in PROTECT (Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function), a trial comparing the effects of rolofylline to placebo in patients with acute heart failure...
January 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28069638/feasibility-and-predictors-of-early-discharge-after-percutaneous-edge-to-edge-mitral-valve-repair
#4
Corrado Tamburino, Sergio Buccheri, Antonio Popolo Rubbio, Salvatore Scandura, Maria Elena Di Salvo, Sarah Mangiafico, Sebastiano Immé, Giuseppe Caruso, Matteo Scalia, Antonio Condorelli, Marco Barbanti, Piera Capranzano, Davide Capodanno, Carmelo Grasso
BACKGROUND: Percutaneous edge-to-edge mitral valve repair (PMVR) recently emerged as an effective treatment modality for patients with severe mitral regurgitation (MR). Length of postprocedural hospital stay may represent a modifiable cost associated with percutaneous treatment. We looked at feasibility, predictors and safety of early discharge (ED), defined as hospital discharge within 72 hours, in patients undergoing PMVR. METHODS AND RESULTS: Consecutive patients treated with MitraClip from October 2008 to December 2015 were analysed...
January 9, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28062629/unraveling-the-molecular-complexity-of-o-glycosylated-endogenous-n-terminal-pro-b-type-natriuretic-peptide-forms-in-blood-plasma-of-patients-with-severe-heart-failure
#5
Bernhard Halfinger, Angelika Hammerer-Lercher, Benno Amplatz, Bettina Sarg, Leopold Kremser, Herbert H Lindner
BACKGROUND: Currently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and its physiologically active counterpart, BNP, are most frequently used as biomarkers for diagnosis, prognosis, and disease monitoring of heart failure (HF). Commercial NT-proBNP and BNP immunoassays cross-react to varying degrees with unprocessed proBNP, which is also found in the circulation. ProBNP processing and immunoassay response are related to O-linked glycosylation of NT-proBNP and proBNP. There is a clear and urgent need to identify the glycosylation sites in the endogenously circulating peptides requested by the community to gain further insights into the different naturally occurring forms...
January 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28062628/specificity-of-b-type-natriuretic-peptide-assays-cross-reactivity-with-different-bnp-nt-probnp-and-probnp-peptides
#6
Amy K Saenger, Olaia Rodriguez-Fraga, Ranka Ler, Jordi Ordonez-Llanos, Allan S Jaffe, Jens Peter Goetze, Fred S Apple
BACKGROUND: B-type natriuretic peptides (BNPs) are used clinically to diagnose and monitor heart failure and are present in the circulation as multiple proBNP-derived fragments. We investigated the specificity of BNP immunoassays with glycosylated and nonglycosylated BNP, N-terminal proBNP (NT-proBNP), and proBNP peptides to probe the cross-reactivity of each assay. METHODS: Nine B-type natriuretic peptides were studied,including synthetic and recombinant BNP (Shionogi, Scios, Mayo), human and synthetic glycosylated and nonglycosylated NT-proBNP (HyTest, Roche Diagnostics), and human glycosylated and nonglycosylated proBNP (HyTest, Scios)...
January 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28062615/biochemistry-therapeutics-and-biomarker-implications-of-neprilysin-in-cardiorenal-disease
#7
REVIEW
Yang Chen, John C Burnett
BACKGROUND: Neprilysin (NEP) is a membrane-bound neutral endopeptidase that degrades a variety of bioactive peptides. The substrates include natriuretic peptides (NPs), which are important regulating mediators for cardiovascular and renal biology. Inhibition of NEP activity and exogenous NP administration thus have emerged as potential therapeutic strategies for treating cardiorenal diseases. More recently, B-type natriuretic peptide (BNP) or N-terminal-proBNP (NT-proBNP), 3'-5' cyclic guanosine monophosphate (cGMP), and soluble NEP as biomarkers have also been investigated in heart failure (HF) trials and their predictive value are beginning to be recognized...
January 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28062134/vascular-expansion-during-worsening-of-heart-failure-effects-on-clinical-features-and-its-determinants
#8
Hajime Kataoka
BACKGROUND: This study investigated the relation of the changes in serum solutes/albumin to the level of vascular expansion and clinical features during worsening HF. METHODS: Data from 47 patients with acute on chronic HF worsening were analyzed. Blood tests included hemoglobin, hematocrit, albumin, solutes (Na/K/Cl/BUN/Cr), and b-type natriuretic peptide (BNP). The relative change in the vascular expansion from stable to worsening HF was estimated based on changes in the plasma volume (%PV)...
December 27, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28052545/safety-feasibility-and-effectiveness-of-first-in-human-administration-of-muscle-derived-stem-progenitor-cells-modified-with-connexin-43-gene-for-treatment-of-advanced-chronic-heart-failure
#9
Adrian Gwizdala, Natalia Rozwadowska, Tomasz Jan Kolanowski, Agnieszka Malcher, Aleksandra Cieplucha, Bartlomiej Perek, Wojciech Seniuk, Ewa Straburzynska-Migaj, Zofia Oko-Sarnowska, Witold Cholewinski, Michal Michalak, Stefan Grajek, Maciej Kurpisz
AIMS: To assess the safety and efficacy of transendocardial delivery of muscle-derived stem/progenitor cells with connexin-43 overexpression (Cx-43-MDS/PC) in advanced heart failure (HF). METHODS AND RESULTS: Thirteen subjects with advanced HF, New York Heart Association (NYHA) class II-III were enrolled and treated with targeted injection of Cx-43-MDS/PCs and then monitored for at least 6 months. Overexpression of Cx43 (Cx43+) was significantly higher in all but one subject (Cx43-)...
January 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28050472/use-of-lung-ultrasound-for-diagnosing-acute-heart-failure-in-emergency-department-of-southern-india
#10
Manav Aggarwal, Mrigakshi Gupta, Vikrant Vijan, Anjith Vupputuri, Sanjeev Chintamani, Bishnukiran Rajendran, Rajesh Thachathodiyal, Rajiv Chandrasekaran
INTRODUCTION: Diagnosing heart failure is often a challenge for the healthcare providers due to it's non-specific and usually subtle physical presentations. The outcomes for treatment are strongly related to the stage of the disease. Considering the importance of early and accurate diagnosis, it is important to have an easy, inexpensive, non-invasive, reliable and reproducible method for diagnosis of heart failure. Recent advancement in radiology and cardiology are supporting the emerging technique of lung ultrasound through B-line evaluation for identifying extravascular lung water...
November 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28045413/vitamin-d-levels-predict-the-response-to-cardiac-resynchronization-therapy-in-patients-with-systolic-heart-failure
#11
Hamza Sunman, Adem Özkan, Hikmet Yorgun, Uğur Canpolat, Naresh Maharjan, Serkan Asil, Ergün Barış Kaya, Tülin Bayrak, Lale Tokgözoğlu, Asuman Özkara, Kudret Aytemir, Ali Oto
OBJECTIVE: The aim of this study was to examine the relationship between vitamin D levels in patients with heart failure (HF) and response to cardiac resynchronization therapy (CRT). METHODS: We studied 57 patients (mean age: 60.47±13.09 years) with New York Heart Association Class II or III heart failure, QRS duration ?120 milliseconds, and ejection fraction <35% (mean: 27.1±4.4%) who underwent CRT. All patients were taking optimal medical treatment for HF...
December 2016: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28043438/surgical-experience-and-long-term-results-of-baroreflex-activation-therapy-for-heart-failure-with-reduced-ejection-fraction
#12
Fred A Weaver, William T Abraham, William C Little, Christian Butter, Anique Ducharme, Marcel Halbach, Didier Klug, Eric G Lovett, Navid Madershahian, Jochen Müller-Ehmsen, Jill E Schafer, Michele Senni, Vijay Swarup, Rolf Wachter, Michael R Zile
The purpose of this publication is to describe the intraoperative experience along with long-term safety and efficacy of the second-generation baroreflex activation therapy (BAT) system in patients with heart failure (HF) and reduced ejection fraction HF (HFrEF). In a randomized trial of New York Heart Association Class III HFrEF, 140 patients were assigned 1:1 to receive BAT plus medical therapy or medical therapy alone. Procedural information along with safety and efficacy data were collected and analyzed over 12 months...
July 2016: Seminars in Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28042816/the-role-of-omega-3-polyunsaturated-fatty-acids-in-heart-failure-a-meta-analysis-of-randomised-controlled-trials
#13
Chunbin Wang, Bo Xiong, Jing Huang
Many new clinical trials about the effect of omega-3 polyunsaturated fatty acids (PUFAs) in heart failure (HF) patients have shown inconsistent results. Therefore, a meta-analysis of randomised controlled trials (RCTs) was performed to determine the benefits of omega-3 PUFAs in HF patients. Articles were obtained from PubMed, EMBASE, and the Cochrane Library. RCTs comparing omega-3 PUFAs with placebo for HF were included. Two reviewers independently extracted the data from the selected publications. The I² statistic was used to assess heterogeneity...
December 30, 2016: Nutrients
https://www.readbyqxmd.com/read/28038863/association-of-remote-ischemic-peri-conditioning-with-reduced-incidence-of-clinical-heart-failure-after-primary-percutaneous-coronary-intervention
#14
Adetola Ladejobi, Max Wayne, Christian Martin-Gill, Francis X Guyette, Andrew D Althouse, Michael S Sharbaugh, Steven E Reis, Clifton W Callaway, John A Kellum, A J Conrad Smith, Catalin Toma, Oladipupo Olafiranye
BACKGROUND: Clinical heart failure (HF) occurs frequently after ST-segment elevation myocardial infarction (STEMI), and is associated with increased mortality. We assessed the impact of remote ischemic peri-conditioning (RIPC) during inter-facility air medical transport of STEMI patients on clinical HF following primary percutaneous coronary intervention (pPCI). METHODS: Data from Acute Coronary Treatment and Intervention Outcomes Network Registry®-Get With the Guidelines™ (ACTION Registry-GWTG) from two PCI-hospitals that are utilizing RIPC during inter-facility helicopter transport of STEMI patients for pPCI between March, 2013 and September, 2015 were used for this study...
December 15, 2016: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/28038813/dipstick-proteinuria-is-a-prognostic-indicator-of-short-term-mortality-in-patients-with-heart-failure
#15
Yuanhan Chen, Lu Cai, Zhiming Du, Jiaqi Xu, Ning Tan, Zhiming Ye, Shuangxin Liu, Wei Dong, Wei Shi, Xinling Liang
BACKGROUND: Proteinuria is common in patients with acute heart failure (AHF). This study investigated the relationship between proteinuria and short-term mortality among patients hospitalized for AHF at two university hospitals. METHODS: The death risk was assessed using a 30-day mortality risk score. Of the 1058 eligible patients with AHF, 583 (55.1%) exhibited proteinuria. The degree of proteinuria was positively correlated with poor AHF prognostic indicators (C-reactive protein and N-terminal pro-brain natriuretic peptide) and negatively correlated with protective indicators (basal estimated glomerular filtration rate, haemoglobin, and serum albumin)...
December 21, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28038802/relationship-between-worsening-renal-function-and-long-term-cardiovascular-mortality-in-heart-failure-patients
#16
Toshitaka Okabe, Tadayuki Yakushiji, Takehiko Kido, Yuji Oyama, Wataru Igawa, Morio Ono, Seitaro Ebara, Kennosuke Yamashita, Myong Hwa Yamamoto, Shigeo Saito, Kisaki Amemiya, Naoei Isomura, Hiroshi Araki, Masahiko Ochiai
BACKGROUND: Recently several studies showed that worsening renal function (WRF) during hospitalization might be a strong independent predictor of poor prognosis in decompensated heart failure (HF) patients. However, these studies had a relatively short follow-up duration and their data were limited to in-hospital outcomes. Our purpose was to assess the relationship between WRF and long-term cardiovascular mortality in HF patients. METHODS: We enrolled decompensated HF patients who were admitted to our hospital between April 2010 and March 2015...
December 21, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28031211/model-based-cost-effectiveness-analysis-of-b-type-natriuretic-peptide-guided-care-in-patients-with-heart-failure
#17
Syed Mohiuddin, Barnaby Reeves, Maria Pufulete, Rachel Maishman, Mark Dayer, John Macleod, Theresa McDonagh, Sarah Purdy, Chris Rogers, William Hollingworth
OBJECTIVE: Monitoring B-type natriuretic peptide (BNP) to guide pharmacotherapy might improve survival in patients with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). However, the cost-effectiveness of BNP-guided care is uncertain and guidelines do not uniformly recommend it. We assessed the cost-effectiveness of BNP-guided care in patient subgroups defined by age and ejection fraction. METHODS: We used a Markov model with a 3-month cycle length to estimate the lifetime health service costs, quality-adjusted life years (QALYs) and incremental net monetary benefits (iNMBs) of BNP-guided versus clinically guided care in 3 patient subgroups: (1) HFrEF patients <75 years; (2) HFpEF patients <75 years; and (3) HFrEF patients ≥75 years...
December 28, 2016: BMJ Open
https://www.readbyqxmd.com/read/28029640/reductions-in-n-terminal-pro-brain-natriuretic-peptide-levels-are-associated-with-lower-mortality-and-heart-failure-hospitalization-rates-in-patients-with-heart-failure-with-mid-range-and-preserved-ejection-fraction
#18
Gianluigi Savarese, Camilla Hage, Nicola Orsini, Ulf Dahlström, Pasquale Perrone-Filardi, Giuseppe M C Rosano, Lars H Lund
BACKGROUND: In heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF), feasible surrogate end points are needed for phase II trials. The aim was to assess whether a reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with improved mortality/morbidity in an unselected population of HFmrEF and HFpEF patients. METHODS AND RESULTS: In the Swedish Heart Failure Registry, HFmrEF (EF=40%-49%) and HFpEF (EF≥50%) patients reporting at least 2 consecutive outpatient NT-proBNP assessments were prospectively studied...
November 2016: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28025867/brain-natriuretic-peptide-usefulness-in-very-elderly-dyspnoeic-patients-the-bed-study
#19
Matthieu Plichart, Galdric Orvoën, Patrick Jourdain, Laurent Quinquis, Joël Coste, Michele Escande, Patrick Friocourt, Elena Paillaud, François-Xavier Chedhomme, Florian Labourée, Clémence Boully, Athanase Benetos, Jean-Jacques Domerego, Michel Komajda, Olivier Hanon
AIMS: To evaluate the interest of brain natriuretic peptide (BNP) for heart failure (HF) diagnosis in very old patients. METHODS AND RESULTS: A total of 383 patients aged 80 years or older, hospitalized in geriatrics care for dyspnoea, had a BNP measurement at the acute phase. Independent cardiologists blinded to BNP values classified the patients into cardiac vs. respiratory aetiology according to the European Society of Cardiology guidelines. Mean (SD) age was 88...
December 26, 2016: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28009952/hemodynamic-improvement-at-three-months-after-mitraclip%C3%A3-%C3%A2-treatment-in-end-stage-heart-failure-patients-with-functional-mitral-regurgitation
#20
Sebastian Barth, Martina B Hautmann, Sebastian Kerber, Frank Gietzen, Michael Zacher, Philipp Halbfass, Patrick Müller, Anja Schade, Thomas Deneke, Anno Diegeler, Bernhard Schieffer, Karsten Hamm
BACKGROUND: Functional mitral regurgitation (FMR) is common in patients with advanced heart failure and impaired left ventricular function. The study aim was to examine functional and hemodynamic effects at three months after MitraClip® implantation in high-risk surgical patients with FMR. METHODS: A group of 93 patients was rejected for surgical treatment by heart-team decisions due to an inacceptable risk for conventional mitral valve surgery. Between October 2011 and May 2015, 89 of these patients (96%) were treated successfully with MitraClip implantation...
July 2016: Journal of Heart Valve Disease
keyword
keyword
110869
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"